More than 40 organizations, including the AHA, today urged House and Senate leaders to swiftly pass the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974/H.R. 2212). The legislation would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. “The CREATES Act is a narrowly targeted, bipartisan, pro-competition and market-based solution to these abuses that cost patients, job-creators and taxpayers billions of dollars each year,” the letter states. “…We thank the bipartisan, bicameral sponsors of this important legislation for the work that they have done to, in the words of FDA Commissioner Scott Gottlieb, ‘end the shenanigans’ by certain brand name companies, and we strongly encourage Congress to pass the CREATES Act without delay.”

Related News Articles

Headline
Nearly 70 organizations, including the AHA, today urged congressional leaders to advance the House-passed Pandemic and All-Hazards Preparedness…
Headline
About 34 percent of uninsured U.S. adults did not take their medication as prescribed in 2017 in order to reduce their prescription drug costs, according to a…
Perspective
As our country works to expand health coverage and improve access to care, “Medicare for All” is getting a lot of attention. There are many different flavors…
Headline
Reps. Terri Sewell, D-Ala., and John Katko, R-N.Y., today introduced the Resident Physician Shortage Reduction Act of 2019 (H.R. 1763) that would add up to 15,…
Headline
Legislative proposals for a Medicare public option could negatively affect patient access to care and significantly reduce payments to hospitals, AHA Executive…
Headline
The Centers for Medicare & Medicaid Services today updated its Medicare and Medicaid drug spending dashboards with 2017 data.